👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Arteris CEO Charles Janac sells shares worth over $100,000

Published 04/10/2024, 22:12
AIP
-

In recent transactions, Charles K. Janac, President and CEO of Arteris, Inc. (NASDAQ:AIP), sold a significant number of shares in the semiconductor company. The transactions, which took place on October 2nd and 3rd, involved the sale of Arteris common stock for a total value exceeding $100,000.

On October 2nd, Janac sold two separate batches of 2,760 shares each, both at a price of $7.1801 per share, resulting in a total amount of $39,634 for these transactions. The following day, he sold an additional 9,168 shares at a weighted average sale price of $7.0875 per share, totaling $64,978. The sales were made in multiple transactions at prices ranging from $6.99 to $7.22.

These sales were partly to satisfy the CEO's tax liability arising from the release of restricted stock units, as indicated in the footnotes of the filing. Moreover, the transactions on October 3rd were conducted under a 10b5-1 trading plan, which Janac had adopted earlier in the year on February 27, 2024.

After these transactions, Janac still holds a substantial number of shares directly and indirectly through entities where he has voting and dispositive power. Specifically, Bayview Legacy, LLC, where Janac serves as the manager, holds over 10 million shares, and the Charles & Lydia Janac Trust, where he acts as trustee, holds over 63,000 shares.

Investors often monitor insider transactions as they provide insights into executives' perspectives on the company's current valuation and future prospects. The recent sales by Arteris' CEO may be of particular interest to shareholders and potential investors as they evaluate their positions in the company.

The transactions were publicly reported in accordance with SEC regulations, and the details have been made available to the issuer, security holders, and the Securities and Exchange Commission staff upon request.

In other recent news, Arteris, Inc. has been experiencing a series of significant developments. The company has announced a robust Q2 performance, with an annual contract value plus royalties of $60.1 million and a total revenue for the quarter standing at $14.6 million. This success is largely attributed to the addition of seven new customers and the signing of four new license deals with existing clients.

The company has also recently welcomed Joachim Kunkel to its Board of Directors. Kunkel, a former General Manager of the IP business unit at Synopsys (NASDAQ:SNPS), brings over three decades of experience to Arteris.

Looking ahead, Arteris projects its annual contract value plus royalties to range between $58.5 million and $62.5 million for Q3, with revenues estimated at $14.2 million to $15.2 million. For the full year of 2024, the company's guidance includes an annual contract value plus royalties of $62 million to $68 million and revenue of $56 million to $58 million. These recent developments suggest a positive trajectory for Arteris in the semiconductor industry.

InvestingPro Insights

To provide additional context to Charles K. Janac's recent stock sales, it's worth examining some key financial metrics and analyst perspectives on Arteris, Inc. (NASDAQ:AIP). According to InvestingPro data, the company's market capitalization stands at $278.73 million, reflecting its current position in the semiconductor industry.

Arteris boasts impressive gross profit margins, with the latest figures showing a robust 89.39% for the last twelve months as of Q2 2023. This strength in profitability at the gross level is highlighted as one of the InvestingPro Tips, suggesting that the company has significant pricing power or efficient production processes.

However, investors should note that Arteris is not currently profitable, with a negative P/E ratio of -7.27 for the same period. This aligns with another InvestingPro Tip indicating that analysts do not anticipate the company to be profitable this year. Despite this, it's encouraging to see that 4 analysts have revised their earnings upwards for the upcoming period, potentially signaling improving expectations for the company's financial performance.

The company's revenue for the last twelve months as of Q2 2023 was $53.3 million, with a modest growth of 3.12% over the same period. While this growth is positive, it's relatively modest and may explain some of the caution reflected in the stock's performance and insider selling activity.

For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights beyond those mentioned here. In fact, there are 7 more InvestingPro Tips available for Arteris, which could provide valuable perspective on the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.